SCHEMBL162189

SCHEMBL162189

CNC(=O)c1ccccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
KDM4E B2RXH2 2/20 0.59
HTT P42858 1/20 0.59
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
NAPRT Q6XQN6 1/20 0.57
P4HTM Q9NXG6 1/20 0.57
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30037891 1.00 ALDH1A1 (0.61) ALDH1A1CES2CES1KDM4EHTT
Hydrochloric Acid SCHEMBL29898692 0.98 ALDH1A1 (0.59) ALDH1A1CES2CES1KDM4EHTT
Hydrochloric Acid SCHEMBL1291172 0.98 ALDH1A1 (0.59) ALDH1A1CES2CES1KDM4EHTT
Water SCHEMBL30018403 0.98 ALDH1A1 (0.59) ALDH1A1CES2CES1KDM4EHTT
Hydrochloric Acid SCHEMBL6385940 0.98 ALDH1A1 (0.59) ALDH1A1CES2CES1KDM4EHTT
Naphthalene SCHEMBL28148133 0.94 ALDH1A1 (0.55) ALDH1A1CES2CES1KDM4EHTT
SCHEMBL12505347 0.93 NPC1 (0.57) ALDH1A1CES2CES1KDM4EHTT
Trifluoroacetic Acid SCHEMBL30663246 0.88 TLR7 (0.52) ALDH1A1CES2CES1KDM4EHTT
SCHEMBL14574955 0.86 ALDH1A1 (0.55) ALDH1A1CES2CES1KDM4EHTT
SCHEMBL12505346 0.85 PTGS2 (0.61) ALDH1A1KDM4EHTTLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059929-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-19 CN claimed
CN-122036687-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN claimed
CN-122036686-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN claimed
CN-122028654-A Biological memristor for periodontitis detection and preparation method and application thereof 西安交通大学口腔医院 2026-05-12 CN claimed
CN-122010903-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-12 CN claimed
EP-4709714-A1 SUBSTITUTED QUINOXALINES Mirati Therapeutics, Inc. (US) 2026-03-18 EP claimed
EP-4452256-B1 METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS ASTRAZENECA AB (SE) 2025-12-10 EP claimed
EP-4658657-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Mirati Therapeutics, Inc. (US) 2025-12-10 EP claimed
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US claimed
US-20250368615-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2025-12-04 US claimed
EP-1467736-A2 ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES Bayer Pharmaceuticals Corporation (US) 2004-10-20 EP claimed
US-20040053975-A1 Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night KOS LIFE SCIENCES, INC. 2004-03-18 US claimed
WO-2003059354-A2 ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO claimed
US-6172064-B1 METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS GLAXO WELLCOME INC. 2001-01-09 US claimed
EP-1017390-A2 COMBINATIONS OF HMG-COA INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT KOS PHARMACEUTICALS, INC. (US) 2000-07-12 EP claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1999006052-A9 METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID KOS PHARMA INC (US) 1999-04-29 WO claimed
WO-1999006035-A2 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT KOS PHARMACEUTICALS, INC. (US) 1999-02-11 WO claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368615-A1 CHEMICAL COMPOUNDS CYP11B2, CYP11B1, CYP4B1 ALDH1A1 123/4885CES2 227/4885CES1 780/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 ALDH1A1 1738/4885CES2 3332/4885CES1 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.